Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP-PA02 bacteriophage in non-cystic fibrosis bronchiectasis with Pseudomonas aeruginosa
NCT05616221Phase 2Completed
- Sponsor
- Armata Pharmaceuticals
- Start
- Jan 2023
- Primary completion
- Jul 2024
- Modality
- Single Strain Products, Multi-strain Products
- Countries
- 1
01
Overview
A Phase 2 trial of AP-PA02 in Pseudomonas aeruginosa lung infection, sponsored by Armata Pharmaceuticals. Started Jan 2023; status: completed.
02
Drugs
AP-PA02
03
Conditions
Pseudomonas aeruginosa lung infection
Beyond the preview
Go deeper on NCT05616221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05616221.